8 completed, 1 terminated, 1 unknown. 10 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Chronic Hepatitis C Virus Infection: new trials by email Literature Review of Chronic Hepatitis C Virus Infection trials Research Report on Chronic Hepatitis C Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients SOF plus (OBV/PTV/r) plus RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 113 | 2017-03-01 | 2020-05-18 |
| ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants SOF/SMV/DCV/RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 94 | 2017-03-01 | 2020-05-14 |
| Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 (SOF and DCV), (SOF, DCV, and RBV) - Chronic Hepatitis C Virus Infection | Phase 2 / Phase 3 | Completed | Beni-Suef University | 946 | 2016-04-01 | 2020-05-15 |
| Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Sofosbuvir + Simeprevir + Ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | Beni-Suef University | 203 | 2015-04-01 | 2020-05-12 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection OBV/PTV/r, Sofosbuvir, Ribavirin (RBV) - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie | 70 | 2014-12-19 | 2021-07-12 |
| A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 152 | 2010-08-01 | 2020-09-30 |
| A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Interferon α-5, Interferon-α5 plus Interferon-α 2b, Interferon α-2b (INTRON® A) - Chronic Hepatitis C Virus Infection, Genotype 1 | Phase 1 / Phase 2 | Completed | Digna Biotech S.L. | 70 | 2010-05-01 | 2013-02-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ABT-333, Placebo for ABT-333, Pegylated interferon - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 30 | 2009-03-01 | 2018-07-02 |
| Study of CTS-1027 in Hepatitis C Patients CTS-1027, Placebo - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | Conatus Pharmaceuticals Inc. | 87 | 2007-12-01 | 2010-09-16 |
| Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients CHRONVAC-C® - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Unknown | Tripep AB | 12 | 2007-10-01 | 2010-02-10 |
Hepatitis C (1) · Hepatitis C, Chronic (1) · Recurrence (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood-Borne Infections (1) · Chronic Disease (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · Hepatitis (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Infections (1) · Liver Diseases (1) · RNA Virus Infections (1) · Virus Diseases (1)
Ribavirin (5) · Sofosbuvir (2) · ombitasvir (2) · paritaprevir (2) · Introns (1) · Ritonavir (1) · Simeprevir (1) · daclatasvir (1) · dasabuvir (1) · lomibuvir (1) · peginterferon alfa-2a (1) · telaprevir (1)
Beni-Suef University (4) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Conatus Pharmaceuticals Inc. (1) · Digna Biotech S.L. (1) · Tripep AB (1) · Vertex Pharmaceuticals Incorporated (1)
United States (3) · Egypt (2) · New Zealand (1) · Puerto Rico (1) · Spain (1) · Sweden (1)
Anders Vahlne, Professor (1) · Daniel Cohen, MD (1) · Mariem Charafeddine, MD (1) · Mohammed Abdel-Gabbar, Ass. Prof (1) · Ola RH Weiland, Professor (1) · William Frank, MD (1)
PMID 24901821, PMID 24982088, PMID 26596948, PMID 29546644, PMID 29625827, PMID 29754329, PMID 30598598
2009 (1), 2014 (1)